Imiquimod (IMQ)-induced psoriasis-like skin inflammation model reduces the suppressive activity of Treg, and then upregulates IL-17 and IL-6, and downregulates IL-10 and FOXP3, whereas butyrate can reverse these progressions by inhibiting HDACs (Schwarz et al., 2021) (Figure 1). The gene discussed is IL6; the disease is dermatitis.